Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease

Barrie Cohen, Gitit Tomer, Tatyana Gavrilova

Research output: Contribution to journalArticlepeer-review


Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis to the medication after the second dose. A drug desensitization protocol was created by the allergy team leading to successful administration of both intravenous and then subcutaneous ustekinumab. As monoclonal agents become mainstays of therapy for inflammatory conditions, there are increased reports of allergic reactions. Prior reports and protocols of ustekinumab desensitization have not been reported. This case report highlights successful desensitization to ustekinumab as well as the importance of a multidisciplinary approach to addressing treatment needs of patients who develop life-threatening reactions to such medications.

Original languageEnglish (US)
Pages (from-to)657-661
Number of pages5
JournalCase Reports in Gastroenterology
Issue number2
StatePublished - Jul 20 2021


  • Crohn's disease
  • Desensitization
  • Ustekinumab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease'. Together they form a unique fingerprint.

Cite this